Specify a stock or a cryptocurrency in the search bar to get a summary
Longboard Pharmaceuticals Inc
LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. Address: 4275 Executive Square, La Jolla, CA, United States, 92037
Analytics
WallStreet Target Price
63.29 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LBPH
Dividend Analytics LBPH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LBPH
Stock Valuation LBPH
Financials LBPH
Results | 2019 | Dynamics |